Doxorubicin liposomal - Innomedica

Drug Profile

Doxorubicin liposomal - Innomedica

Alternative Names: Talidox; Targeted liposomal doxorubicin; TLD; TLD-1

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InnoMedica
  • Developer InnoMedica; Mario Negri Institute for Pharmacological Research
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 25 Apr 2017 Innomedica and Swiss Association for Clinical Cancer Research (SAKK) plan a dose escalation phase I trial for Solid tumours in Switzerland (NCT03387917)
  • 25 Apr 2017 Innomedica and Swiss Association for Clinical Cancer Research (SAKK) plan a phase IIb/III trial for Solid tumours in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top